COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
Aveo models tumor biology to develop targeted cancer therapeutics, advancing EGFR inhibitor AV-412 (in-licensed from Mitsubishi Pharma) through early-stage human testing for resistant tumors.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
